Prof. Laurence Albiges (MD, PhD) is a medical Oncologist dedicated to genitourinary malignancies and her main research focus is renal cell carcinoma (RCC). She has trained and became faculty at Gustave Roussy since 2013. She is involved in the development of targeted agents and immune checkpoint blockers for metastatic RCC. Dr Albiges is the PI of investigator-initiated and industry-sponsored phase II and phase III trials of new agents in metastatic RCC. She works in close collaboration with early drug department for phase I trials relevant to RCC. Throughout her training and faculty positions, she has created collaboration with major RCC clinical research center in Europe and worldwide States and built translational collaborations funded both from academic and industry support. Dr Albiges is heavily committed to teaching, training and mentoring in the field of medical oncology (University Paris Sud - Paris Saclay) and have launched a specific diploma (DIU) across 3 Universities focused on Genitourinary Oncology teaching for medical Oncologist, Urologist and Radiation oncologist. She was certified with a medical pedagogy degree in 2018. She has been elected Gustave Roussy representative for Paris Saclay Medical School University council since 2015 and has been re-elected for a second term since 2020. From a clinical and institutional standpoint, she chaired the largest academic genitourinary oncology (GU) group in France from 2015 to 2021. Gustave Roussy GU group manage >1100 new patients per year and enrolled over 250 patients in clinical trials every year. After serving as deputy Chair of Gustave Roussy Cancer Medecine Department for 2 years during the pandemic, she was appointed Chair of Gustave Roussy Cancer Department since October 2021. She has been sitting as member of the GETUG board since 2014, and is an active member of both the EAU RCC guidelines panel as well as the ESMO RCC guidelines panel. She is involved in the Scientific committee of the Kidney Cancer Association. Hes research has been published in peer-reviewed journals that include Journal of Clinical Oncology, The New England Journal of Medicine, Clinical Cancer Research, European Urology, European Journal of Cancer, JAMA Oncology, Nature Cancer